Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Bristol-Myers Squibb Company  is placed second among the best cancer stocks on our list. TheFly reported on January 9 that Scotiabank analyst Louise Chen raised BMY’s price target to $60 from $53 while maintaining a Sector Perform rating. According to the analyst, investors find the stock appealing because to its low valuation and a “catalyst-rich” 2026. Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 202 ...